Proteins and Peptides

17 April 2013

Are Erythropoietins still an attractive R&D goal?

11 April 2013

Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

10 April 2013

Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer

10 April 2013

BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia

10 April 2013

Aileron Therapeutics Presents New Preclinical Data on Stapled Peptide Inhibitor of Cancer Transcription Factor HIF-1α at AACR Annual Meeting

8 April 2013

DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval for DM-199 as a Potential Treatment for Diabetes

8 April 2013

Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia

8 April 2013

Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan

8 April 2013

Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013

7 April 2013

Meta-Analysis of VELCADE (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients with Multiple Myeloma

4 April 2013

ProFibrix Completes Patient Enrolment in Pivotal Phase III with FibrocapsTM and Reports Positive Feedback from Surgical Community

3 April 2013

ERYTECH Pharma Receives FDA IND Clearance to Initiate a Clinical Study in Acute Lymphoblastic Leukemia in the U.S.

3 April 2013

Aspireo Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly

3 April 2013

Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun

3 April 2013

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

1 April 2013

BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA

1 April 2013

BioMarin Submits CTA for BMN-190 for Batten Disease

28 March 2013

Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate BIOD-123 for the Treatment of Diabetes

27 March 2013

Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson’s Disease

26 March 2013

iBio Selects Proprietary Recombinant C1 Inhibitor for Clinical Development

26 March 2013

BioSpecifics Technologies Corp. Announces Positive Top-line Data from XIAFLEX Phase IIa Study for Frozen Shoulder

20 March 2013

Novo Nordisk A/S Successfully Completes Phase I Trial of its Proprietary Oral Insulin (NN1954) Using Merrion Pharmaceuticals GIPET Technology

20 March 2013

Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY (Peginterferon Beta-1a) Presented at AAN Meeting

20 March 2013

Adocia announces its phase III development program for the treatment of diabetic foot ulcer

19 March 2013

NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84

18 March 2013

People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial

16 March 2013

ThromboGenics’ JETREA granted EU approval for vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns

16 March 2013

Omni Bio Announces First Results for Its Lead Recombinant Molecule

11 March 2013

Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact

7 March 2013

Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Ranibizumab (Lucentis) Biosimilars Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

TSLP Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review